Coherus BioSciences Files 2024 10-K

Ticker: CHRS · Form: 10-K · Filed: Mar 17, 2025 · CIK: 1512762

Sentiment: neutral

Topics: 10-K, financials, biotech

TL;DR

Coherus BioSciences filed its 2024 10-K. Financials look solid, R&D and SG&A expenses detailed.

AI Summary

Coherus BioSciences, Inc. filed its 2024 10-K on March 17, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing details the company's assets, liabilities, and expenses, including research and development and selling, general, and administrative costs. Coherus BioSciences, formerly BioGenerics, Inc., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This 10-K filing provides a comprehensive overview of Coherus BioSciences' financial health and operational activities for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — The company operates in the highly competitive and regulated biopharmaceutical industry, which carries inherent risks related to drug development, clinical trials, and market adoption.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Coherus BioSciences, Inc.?

Coherus BioSciences, Inc. operates in the biological products sector, specifically focusing on biological products (excluding diagnostic substances).

When was the 10-K filing submitted?

The 10-K filing was submitted on March 17, 2025.

What was the previous name of Coherus BioSciences, Inc.?

The former name of Coherus BioSciences, Inc. was BioGenerics, Inc., with a name change date of February 10, 2011.

Where is Coherus BioSciences, Inc. incorporated?

Coherus BioSciences, Inc. is incorporated in Delaware (DE).

What is the business address of Coherus BioSciences, Inc.?

The business address is 333 Twin Dolphin Dr, Suite 600, Redwood City, CA 94065.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 17, 2025 by Dennis M. Lanfear regarding Coherus BioSciences, Inc. (CHRS).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing